{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:04:57Z","timestamp":1777860297829,"version":"3.51.4"},"reference-count":104,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JRS"],"published-print":{"date-parts":[[2023,9,13]]},"abstract":"<jats:p>BACKGROUND: Epilepsy is one of the most common chronic neurological disorders, affecting more than 50 million people globally. In this review we summarised the evidence from randomised controlled trials of gabapentin used as monotherapy for the treatment of focal epilepsy, both newly diagnosed and drug-resistant, with or without secondary generalisation. OBJECTIVE: To assess the effects of gabapentin monotherapy for people with epileptic focal seizures with and without secondary generalisation. METHODS: We searched the Cochrane Register of Studies (CRS Web) and MEDLINE (Ovid, 1946 to 24 February 2020) on 25 February 2020. CRS Web includes randomised or quasi-randomised controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform, the Cochrane Central Register of Controlled Trials (CENTRA), and the specialised registers of Cochrane Review Groups including the Cochrane Epilepsy Group. We also searched several Russian databases, reference lists of relevant studies, ongoing trials registers, conference proceedings, and we contacted trial authors. RESULTS: We found five randomised controlled trials (3167 participants) comparing gabapentin to other antiepileptic drugs (AEDs) and differing doses of gabapentin as monotherapy for newly diagnosed focal epilepsy and drug- resistant focal epilepsy with or without secondary generalisation. Two review authors independently applied the inclusion criteria, assessed trial quality, risk of bias, and extracted data. We used the GRADE approach to assess the certainty of evidence and present seven patient-important outcomes in the \u201cSummary of findings\u201d tables. The quality of evidence was very low to moderate due to poor reporting quality, poor trial design, and other risks of bias, such as selective presentation of findings and potential heavy industry input. Better quality research may change our certainty in the effect estimates. None of the included trials reported on the number of people with 50% or greater reduction in seizures and time to withdrawal (retention time) in an extractable way. Gabapentin-treated participants were more likely to withdraw from treatment for any cause (285\/539) than those treated with lamotrigine, oxcarbazepine, or topiramate pooled together (695\/1317) (RR 1.13, 95% CI 1.02 to 1.25; 3 studies, 1856 participants; moderate-certainty evidence), but not carbamazepine. Fewer people treated with gabapentin withdrew from treatment owing to adverse events (190\/525) than those treated with carbamazepine, oxcarbazepine, or topiramate (479\/1238), (RR 0.79, 95% CI 0.69 to 0.91; 1763 participants, 3 studies; moderate-certainty evidence), but not lamotrigine. CONCLUSION: Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate). Compared to carbamazepine, gabapentin was probably better in retaining people in studies and preventing withdrawals due to adverse events. The most common side effects associated with gabapentin were ataxia (poor co-ordination and unsteady gait), dizziness, fatigue, and drowsiness.<\/jats:p>","DOI":"10.3233\/jrs-235001","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T11:22:19Z","timestamp":1688124139000},"page":"243-286","source":"Crossref","is-referenced-by-count":8,"title":["Gabapentin monotherapy for epilepsy: A review"],"prefix":"10.1177","volume":"34","author":[{"given":"Liliya Eugenevna","family":"Ziganshina","sequence":"first","affiliation":[{"name":", , , Russian Federation"},{"name":", Kazan State Medical University (KSMU), , , Russian Federation"},{"name":", Peoples\u2019 Friendship University of Russia named after Patrice Lumumba (RUDN), , Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Abakumova","sequence":"additional","affiliation":[{"name":", Kazan (Volga region) Federal University, , Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles H.V.","family":"Hoyle","sequence":"additional","affiliation":[{"name":", , Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"1","key":"10.3233\/JRS-235001_ref1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.03.003","article-title":"The descriptive epidemiology of epilepsy - a review","volume":"85","author":"Banerjee","year":"2009","journal-title":"Epilepsy Research"},{"issue":"4","key":"10.3233\/JRS-235001_ref2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.yebeh.2007.12.019","article-title":"The global burden and stigma of epilepsy","volume":"12","author":"De Boer","year":"2008","journal-title":"Epilepsy & Behavior"},{"issue":"7","key":"10.3233\/JRS-235001_ref3","first-page":"392","article-title":"Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment","volume":"35","author":"Goldenberg","year":"2010","journal-title":"P & T: A Peer-Reviewed Journal for Formulary Management"},{"key":"10.3233\/JRS-235001_ref5","doi-asserted-by":"crossref","unstructured":"ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia. 1998;39(7):799\u2013803.","DOI":"10.1111\/j.1528-1157.1998.tb01167.x"},{"issue":"9566","key":"10.3233\/JRS-235001_ref6","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.3233\/JRS-235001_ref7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: A practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"5","key":"10.3233\/JRS-235001_ref8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1528-1167.2010.02946.x","article-title":"The social and economic consequences of epilepsy: A controlled national study","volume":"52","author":"Jennum","year":"2011","journal-title":"Epilepsia"},{"issue":"3","key":"10.3233\/JRS-235001_ref9","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/epi.13294","article-title":"Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model","volume":"57","author":"Megiddo","year":"2016","journal-title":"Epilepsia"},{"key":"10.3233\/JRS-235001_ref10","first-page":"990","volume-title":"Merritt\u2019s Neurology","author":"Bazil","year":"2005"},{"issue":"8968","key":"10.3233\/JRS-235001_ref11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: Results from the National General Practice Study of Epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"Suppl Florence","key":"10.3233\/JRS-235001_ref12","first-page":"69","article-title":"A double blind study of gabapentin in partial seizures","volume":"41","author":"Kwan","year":"2000","journal-title":"Epilepsia"},{"issue":"2","key":"10.3233\/JRS-235001_ref13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1212\/WNL.49.2.333","article-title":"Difficulties in extrapolating from clinical trial data to clinical practice: The case of antiepileptic drugs","volume":"49","author":"Walker","year":"1997","journal-title":"Neurology"},{"key":"10.3233\/JRS-235001_ref14","doi-asserted-by":"crossref","DOI":"10.1002\/9781118951026","volume-title":"Epilepsy and the Interictal State: Co-morbidities and Quality of Life","author":"St Louis","year":"2015"},{"issue":"8","key":"10.3233\/JRS-235001_ref15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: A systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"10.3233\/JRS-235001_ref16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1157.1999.tb00921.x","article-title":"Gabapentin","volume":"40","author":"Morris","year":"1999","journal-title":"Epilepsia"},{"key":"10.3233\/JRS-235001_ref17","volume-title":"Models of Seizures and Epilepsy","author":"Pitk\u00e4nen","year":"2005"},{"issue":"9566","key":"10.3233\/JRS-235001_ref24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.3233\/JRS-235001_ref25","doi-asserted-by":"crossref","unstructured":"Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews. 2016;11(11).","DOI":"10.1002\/14651858.CD010224.pub2"},{"issue":"Suppl 2","key":"10.3233\/JRS-235001_ref26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1528-1157.1995.tb06001.x","article-title":"Gabapentin","volume":"36","author":"McLean","year":"1995","journal-title":"Epilepsia"},{"issue":"4","key":"10.3233\/JRS-235001_ref27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","article-title":"Narrative review: the promotion of gabapentin: An analysis of internal industry documents","volume":"145","author":"Steinman","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.3233\/JRS-235001_ref28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1371\/journal.pmed.0040134","article-title":"Characteristics and impact of drug detailing for gabapentin","volume":"4","author":"Steinman","year":"2007","journal-title":"PLoS Medicine"},{"issue":"12","key":"10.3233\/JRS-235001_ref29","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/archinternmed.2011.241","article-title":"Study of neurontin: titrate to effect, profile of safety (STEPS) trial: A narrative account of a gabapentin seeding trial","volume":"171","author":"Krumholz","year":"2011","journal-title":"Archives of Internal Medicine"},{"key":"10.3233\/JRS-235001_ref30","volume-title":"Deadly Medicines and Organised Crime. How Big Pharma has Corrupted Healthcare","author":"G\u00f8tzsche","year":"2013"},{"key":"10.3233\/JRS-235001_ref39","doi-asserted-by":"crossref","unstructured":"Panebianco M, Al-Bachari S, Weston J, Hutton JL, Marson AG. Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database of Systematic Reviews. 2021;29(3).","DOI":"10.1002\/14651858.CD001415.pub4"},{"issue":"3","key":"10.3233\/JRS-235001_ref40","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"4","key":"10.3233\/JRS-235001_ref41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: Post-hoc, subgroup analyses of data from the SANAD trial","volume":"11","author":"Bonnett","year":"2012","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.3233\/JRS-235001_ref42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/epi.12913","article-title":"Quality-of- life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with new-onset epilepsy: Findings from the SANAD trial","volume":"56","author":"Jacoby","year":"2015","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref43","first-page":"272","article-title":"Carbamazepine versus gabapentin, lamotrigine, oxcarbazepine and topiramate for epilepsy: Results from arm A of the SANAD trial","volume":"47","author":"Marson","year":"2006","journal-title":"Epilepsia"},{"issue":"9566","key":"10.3233\/JRS-235001_ref44","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: An unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"37","key":"10.3233\/JRS-235001_ref45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11370","article-title":"A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial","volume":"11","author":"Marson","year":"2007","journal-title":"Health Technology Assessment"},{"issue":"4","key":"10.3233\/JRS-235001_ref51","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"Journal of the National Cancer Institute"},{"key":"10.3233\/JRS-235001_ref52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9781119536604.ch10","volume-title":"Cochrane Handbook for Systematic Reviews of Intervention","author":"Deeks","year":"2019"},{"issue":"3","key":"10.3233\/JRS-235001_ref53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref54","first-page":"68","article-title":"Multicenter, double-blind study of gabapentin (GBP; Neurontin\u00ae) monotherapy in hospitalized patients with refractory epilepsy","volume":"36","author":"Bergey","year":"1995","journal-title":"Epilepsia"},{"issue":"3","key":"10.3233\/JRS-235001_ref55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1212\/WNL.49.3.739","article-title":"Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88\/89","volume":"49","author":"Bergey","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.3233\/JRS-235001_ref56","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1212\/WNL.49.3.746","article-title":"Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82\/83","volume":"49","author":"Beydoun","year":"1997","journal-title":"Neurology"},{"key":"10.3233\/JRS-235001_ref57","doi-asserted-by":"crossref","unstructured":"Beydoun A. Monotherapy trials with gabapentin for partial epilepsy. Epilepsia. 1999;40(Suppl 6):13-6; 73\u20134.","DOI":"10.1111\/j.1528-1157.1999.tb00927.x"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref58","first-page":"69","article-title":"Open-label, follow-on study of gabapentin (GBP; Neurontin\u00ae) monotherapy in patients with refractory epilepsy","volume":"36","author":"Crockatt","year":"1995","journal-title":"Epilepsia"},{"issue":"6","key":"10.3233\/JRS-235001_ref59","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00007691-200012000-00017","article-title":"Increased seizures after discontinuing carbamazepine: Results from the gabapentin monotherapy trial","volume":"22","author":"DeToledo","year":"2000","journal-title":"Therapeutic Drug Monitoring"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref60","first-page":"271","article-title":"Gender differences in neuropsychological response to gabapentin","volume":"38","author":"Dodrill","year":"1997","journal-title":"Epilepsia"},{"issue":"2","key":"10.3233\/JRS-235001_ref61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0920-1211(99)00006-6","article-title":"Cognitive abilities and adjustment with gabapentin: Results of a multisite study","volume":"35","author":"Dodrill","year":"1999","journal-title":"Epilepsy. Research"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref62","first-page":"88","article-title":"Evaluation of quality of life during a double-blind multicenter study of gabapentin (GBP: Neurontin\u00ae) monotherapy in patients with medically refractory partial seizures","volume":"36","author":"Dodrill","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref63","first-page":"117","article-title":"Neuropsychological, mood, and psychosocial effects of gabapentin","volume":"33","author":"Dodrill","year":"1992","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref64","first-page":"119","article-title":"Gabapentin (Neurontin) monotherapy in patients with medically refractory partial seizures: an open- label extension study","volume":"36","author":"Garofalo","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref65","first-page":"187","article-title":"Quality of life assessments during open-label multicenter study evaluating gabapentin (Neurontin) monotherapy in medically refractory patients with partial seizures","volume":"36","author":"Garofalo","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"10.3233\/JRS-235001_ref66","first-page":"160","article-title":"Weight changes during a gabapentin (Neurontin\u00ae) 26-week monotherapy trial (945-82)","volume":"37","author":"Garofalo","year":"1996","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref67","first-page":"68","article-title":"An open-label extension study of gabapentin (GBP; Neurontin\u00ae) monotherapy in patients with medically refractory partial seizures","volume":"36","author":"Garofalo","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref68","first-page":"89","article-title":"Baseline predictors of successful monotherapy treatment in a gabapentin (GBP; Neurontin\u00ae) monotherapy, double-blind, dose-controlled, multicenter study","volume":"36","author":"Greiner","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref69","first-page":"119","article-title":"Gabapentin (Neurontin) monotherapy: A double-blind study in patients with medically refractory partial seizures","volume":"36","author":"Hayes","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref70","first-page":"187","article-title":"Quality of life assessments during a double-blind study of gabapentin (Neurontin) in patients with medically refractory partial seizures","volume":"36","author":"Hayes","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.3233\/JRS-235001_ref71","first-page":"164","article-title":"An ongoing open-label multicenter study evaluating gabapentin (Neurontin\u00ae) monotherapy and safety in patients with medically refractory partial seizures","volume":"35","author":"Hayes","year":"1994","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref72","first-page":"89","article-title":"A double- blind multicenter study of gabapentin (GBP; Neurontin\u00ae) monotherapy in patients with medically refractory partial seizures","volume":"36","author":"Hayes","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref73","first-page":"69","article-title":"Gabapentin (Neurontin) monotherapy in men versus women and in patients receiving previous monotherapy versus those receiving previous polytherapy","volume":"37","author":"LaMoreaux","year":"1996","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.3233\/JRS-235001_ref74","first-page":"68","article-title":"Double-blind, multicenter study of gabapentin (Neurontin) monotherapy in hospitalized, refractory patients with epilepsy","volume":"35","author":"Leiderman","year":"1994","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref75","first-page":"S119","article-title":"Gabapentin (Neurontin) as monotherapy in newly diagnosed patients with partial epilepsy","volume":"36","author":"Anhut","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref76","first-page":"34","article-title":"Gabapentin (GBP; Neurontin) monotherapy in patients with newly-diagnosed epilepsy: Results of a double-blind fixed-dose study comparing three dosages of gabapentin and open-label carbamazepine","volume":"38","author":"Chadwick","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref77","first-page":"61","article-title":"Gabapentin (Neurontin) as monotherapy in newly diagnosed patients with partial epilepsy: a fixed-dose comparison study versus carbamazepine","volume":"37","author":"Chadwick","year":"1996","journal-title":"Epilepsia"},{"issue":"5","key":"10.3233\/JRS-235001_ref78","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1212\/WNL.51.5.1282","article-title":"A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945\u201377","volume":"51","author":"Chadwick","year":"1998","journal-title":"Neurology"},{"issue":"Suppl Florence","key":"10.3233\/JRS-235001_ref81","first-page":"138","article-title":"Gabapentin versus lamotrigine monotherapy: A double-blind comparison","volume":"41","author":"Brodie","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.3233\/JRS-235001_ref82","first-page":"177","article-title":"Gabapentin versus lamotrigine monotherapy: A double-blind comparison in newly diagnosed epilepsy","volume":"42","author":"Brodie","year":"2001","journal-title":"Epilepsia"},{"issue":"9","key":"10.3233\/JRS-235001_ref83","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1046\/j.1528-1157.2002.45401.x","article-title":"Gabapentin versus lamotrigine monotherapy: A double-blind comparison in newly diagnosed epilepsy","volume":"43","author":"Brodie","year":"2002","journal-title":"Epilepsia"},{"issue":"11","key":"10.3233\/JRS-235001_ref84","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/01.WNL.0000167384.68207.3E","article-title":"New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine","volume":"64","author":"Rowan","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.3233\/JRS-235001_ref88","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0920-1211(96)00020-4","article-title":"Gabapentin in generalized seizures","volume":"25","author":"Chadwick","year":"1996","journal-title":"Epilepsy Research"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref89","first-page":"59","article-title":"Gabapentin (Neurontin) monotherapy in patients with partial epilepsy: a double-blind flexible dose range comparison study versus carbamazepine","volume":"37","author":"Balkenohl","year":"1996","journal-title":"Epilepsia"},{"key":"10.3233\/JRS-235001_ref90","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0074-7742(06)81017-2","article-title":"Recruitment and retention in clinical trials of the elderly","volume":"81","author":"Macias","year":"2007","journal-title":"International Review of Neurobiology"},{"issue":"7650","key":"10.3233\/JRS-235001_ref91","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.3233\/JRS-235001_ref92","doi-asserted-by":"crossref","unstructured":"Nevitt SJ, Sudell M, Weston J, Tudur Smith C, Marson AG. Antiepileptic drug monotherapy for epilepsy: A network meta-analysis of individual participant data. Cochrane Database of Systematic Reviews. 2017;29(6).","DOI":"10.1002\/14651858.CD011412.pub2"},{"issue":"8","key":"10.3233\/JRS-235001_ref93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2010.03.004","article-title":"CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Moher","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.3233\/JRS-235001_ref94","doi-asserted-by":"crossref","unstructured":"Ziganshina LE, Abakumova T. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. 2015(6).","DOI":"10.1002\/14651858.CD007026.pub3"},{"issue":"4","key":"10.3233\/JRS-235001_ref95","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1212\/WNL.0b013e3181ea157e","article-title":"Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior","volume":"75","author":"Andersohn","year":"2010","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref96","first-page":"32","article-title":"Effects of gabapentin (GBP, Neurontin) on cognitive functioning and mood","volume":"36","author":"Arnett","year":"1995","journal-title":"Epilepsia"},{"key":"10.3233\/JRS-235001_ref97","first-page":"93","article-title":"Gabapentin and Lamotrigine TDM in resistant partial complex seizures","volume":"99","author":"Benetello","year":"1997","journal-title":"Bollettino - Lega Italiana Contro L\u2019Epilessia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref98","first-page":"33","article-title":"Gabapentin and lamotrigine TDM in resistant partial complex seizures","volume":"38","author":"Benetello","year":"1997","journal-title":"Epilepsia"},{"issue":"10","key":"10.3233\/JRS-235001_ref99","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1528-1157.1997.tb01204.x","article-title":"Oral gabapentin disposition in patients with epilepsy after a high-protein meal","volume":"38","author":"Benetello","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref100","first-page":"35","article-title":"Oral gabapentin disposition in epileptic patients after high-protein meal","volume":"38","author":"Benetello","year":"1997","journal-title":"Epilepsia"},{"issue":"3","key":"10.3233\/JRS-235001_ref101","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0920-1211(95)00026-7","article-title":"Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures","volume":"21","author":"Ben-Menachem","year":"1995","journal-title":"Epilepsy Research"},{"issue":"6","key":"10.3233\/JRS-235001_ref102","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00002826-199512000-00001","article-title":"Gabapentin: Pharmacokinetics, efficacy, and safety","volume":"18","author":"Beydoun","year":"1995","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"10.3233\/JRS-235001_ref103","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1528-1157.1998.tb01357.x","article-title":"Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy","volume":"39","author":"Beydoun","year":"1998","journal-title":"Epilepsia"},{"key":"10.3233\/JRS-235001_ref104","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2377-10-104","article-title":"Pregabalin versus gabapentin in partial epilepsy: A meta-analysis of dose-response relationships","volume":"10","author":"Delahoy","year":"2010","journal-title":"BMC Neurology"},{"issue":"2-3","key":"10.3233\/JRS-235001_ref105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-0404.1996.tb00179.x","article-title":"Gabapentin in refractory partial epilepsy - a trial in India","volume":"93","author":"Dixit","year":"1996","journal-title":"Acta Neurologica Scandinavica"},{"issue":"8","key":"10.3233\/JRS-235001_ref106","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/epi.13435","article-title":"Seizure outcome after switching antiepileptic drugs: A matched, prospective study","volume":"57","author":"Finamore","year":"2016","journal-title":"Epilepsia"},{"issue":"4","key":"10.3233\/JRS-235001_ref107","first-page":"299","article-title":"Anticonvulsant drug hypersensitivity","volume":"12","author":"Galindo","year":"2002","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"issue":"8","key":"10.3233\/JRS-235001_ref108","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1528-1157.1999.tb00830.x","article-title":"A beneficial effect on mood in partial epilepsy patients treated with gabapentin","volume":"40","author":"Harden","year":"1999","journal-title":"Epilepsia"},{"issue":"Suppl Florence","key":"10.3233\/JRS-235001_ref109","first-page":"38","article-title":"Efficacy of therapy with new antiepileptic drugs (tiagabine, gabapentin, topiramate) in drug-resistant epilepsy","volume":"41","author":"Kazibutowska","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.3233\/JRS-235001_ref110","first-page":"45","article-title":"Gabapentin patients with absence seizures: two double-blind, placebo controlled studies","volume":"34","author":"Leiderman","year":"1993","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref111","first-page":"17","article-title":"Gabapentin vs valproate in partial epilepsy uncontrolled by carbamazepin","volume":"6","author":"Lopes-Lima","year":"1999","journal-title":"European Journal of Neurology"},{"issue":"5","key":"10.3233\/JRS-235001_ref112","first-page":"9","article-title":"A study of efficiency and safety of gabapentin in treatment of patients with epilepsy","volume":"24","author":"Ma","year":"2003","journal-title":"Journal of Mudanjiang Medical College"},{"issue":"3","key":"10.3233\/JRS-235001_ref113","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.braindev.2013.04.006","article-title":"The efficacy of gabapentin in children of partial seizures and the blood levels","volume":"36","author":"Nonoda","year":"2014","journal-title":"Brain & Development"},{"issue":"5","key":"10.3233\/JRS-235001_ref114","first-page":"735","article-title":"Gabapentin monotherapy for partial seizures: A promising option","volume":"30","author":"Ojemann","year":"1989","journal-title":"Epilepsia"},{"issue":"37","key":"10.3233\/JRS-235001_ref115","first-page":"1430","article-title":"Trials with Gabapentin monotherapy in patients with complex partial or secondary generalized seizures","volume":"86","author":"Pierce","year":"1997","journal-title":"Praxis"},{"issue":"5 Suppl 1","key":"10.3233\/JRS-235001_ref116","first-page":"25","article-title":"Effect of anticonvulsants on nocturnal sleep in epilepsy","volume":"54","author":"Placidi","year":"2000","journal-title":"Neurology"},{"issue":"1-3","key":"10.3233\/JRS-235001_ref117","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0920-1211(01)00220-0","article-title":"Monotherapy trials: presurgical studies","volume":"45","author":"Pledger","year":"2001","journal-title":"Epilepsy Research"},{"key":"10.3233\/JRS-235001_ref118","unstructured":"Anonymous. Gabapentin: new indication. Little impact on partial epilepsy in children between 3 and 12. Prescrire International. 2002;11(58):47\u20138."},{"issue":"Suppl 1","key":"10.3233\/JRS-235001_ref119","doi-asserted-by":"crossref","first-page":"85","DOI":"10.33588\/rn.35S1.2002190","article-title":"Characteristics and indications of gabapentin","volume":"35","author":"Sancho-Rieger","year":"2002","journal-title":"Revista de Neurologia"},{"key":"10.3233\/JRS-235001_ref120","first-page":"185","article-title":"Gabapentin versus carbamazepine: Monotherapy in newly-diagnosed patients with partial epilepsy: Preliminary results","volume":"95-96","author":"Sasanelli","year":"1996","journal-title":"Bollettino - Lega Italiana Contro L\u2019Epilessia"},{"issue":"2","key":"10.3233\/JRS-235001_ref121","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1684\/epd.2014.0650","article-title":"Early add-on treatment vs alternative monotherapy in patients with partial epilepsy","volume":"16","author":"Semah","year":"2014","journal-title":"Epileptic Disorders"},{"issue":"4","key":"10.3233\/JRS-235001_ref122","first-page":"94","article-title":"Clinical studies on gabapentin in Switzerland","volume":"85","author":"Shokry","year":"1996","journal-title":"Praxis"},{"issue":"10","key":"10.3233\/JRS-235001_ref123","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/archneur.1994.00540220095019","article-title":"Long-term study with gabapentin in patients with drug-resistant epileptic seizures","volume":"51","author":"Sivenius","year":"1994","journal-title":"Archives of Neurology"},{"issue":"Suppl 4","key":"10.3233\/JRS-235001_ref124","first-page":"68","article-title":"Gabapentin (GBP; Neurontin\u00ae) monotherapy compared with carbamazepine (CBZ) monotherapy and combination GBP plus CBZ (GBP\/CBZ) therapy in patients with medically refractory partial seizures: A 3-way cross-over trial","volume":"36","author":"Trudeau","year":"1995","journal-title":"Epilepsia"},{"issue":"6","key":"10.3233\/JRS-235001_ref125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/088307389601100611","article-title":"Gabapentin in naive childhood absence epilepsy: Results from two double-blind, placebo-controlled, multicenter studies","volume":"11","author":"Trudeau","year":"1996","journal-title":"Journal of Child Neurology"},{"issue":"5","key":"10.3233\/JRS-235001_ref126","first-page":"644","article-title":"Safety and effectiveness of gabapentin in the treatment of partial seizures","volume":"31","author":"Wiener","year":"1990","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.3233\/JRS-235001_ref127","first-page":"77","article-title":"Gabapentin and carbamazepine as monotherapy and combined: A pilot study","volume":"33","author":"Wilensky","year":"1992","journal-title":"Epilepsia"},{"issue":"10","key":"10.3233\/JRS-235001_ref128","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1528-1157.1999.tb02017.x","article-title":"The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy","volume":"40","author":"Wong","year":"1999","journal-title":"Epilepsia"},{"issue":"2","key":"10.3233\/JRS-235001_ref129","first-page":"92","article-title":"Curative effect of gabapentin on refractory epilepsy","volume":"85","author":"Zhu","year":"2005","journal-title":"Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JRS-235001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:45:36Z","timestamp":1777509936000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JRS-235001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":104,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jrs-235001","relation":{},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}